In a statement issued, ICMR said, “The vaccine will be developed by using the virus strain isolated at the ICMR’s National Institute of Virology (NIV) in Pune.”
Adding to the statement, the health research body said, “Work on vaccine development has been initiated between the two partners. The ICMR-NIV will provide continuous support to BBIL for vaccine development.”
“ICMR and BBIL will seek fast-track approvals to expedite vaccine development, subsequent animal studies, and clinical evaluation of the candidate vaccine,” it added.
“The strain has been successfully transferred from NIV to BBIL,” the statement further added.